China
Biointron, a dynamic player in the Biotechnology and Health Care industries, was founded in 2012 and is headquartered in China. The company is renowned for its efficient antibody discovery and expression services, with a unique capability to deliver from gene sequence to purified antibody in just two weeks, encapsulated by its slogan: “Recombinant Antibody Expression, Delivery in 2 weeks”.
With ISO 9001:2015 certification and recognition as a high-technology enterprise, Biointron has successfully collaborated with over 2,500 pharmaceutical companies in 20 countries. Their global presence is further strengthened by the commercialization reauthorization for ECACC's CHO-K1 cell line and significant collaborations meeting multicenter clinical requirements, including those with the U.S. FDA.
Their impressive trajectory attracted a CNY500.00M Series B investment in August 2022, backed by prominent investors including Joy Capital, University Ventures, Gaorong Capital, and numerous others. These investments underscore the confidence in Biointron's innovative path and growth potential within the global biotech sector.
